Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

Neoplasia (United States)

Volumn 16, Issue 6, 2014, Pages 501-510

  Hasnis, Erez ^a,b   Alishekevitz, Dror ^a   Gingis Veltski, Svetlana ^a   Bril, Rotem ^a   Fremder, Ella ^a   Voloshin, Tali ^a   Raviv, Ziv ^a   Karban, Amir ^b   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Department of Internal Medicine C ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907394550     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.05.011     Document Type: Article

References (41)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Kleeff J., Beckhove P., Esposito I., Herzig S., Huber P.E., Lohr J.M., Friess H. Pancreatic cancer microenvironment. Int J Cancer 2007, 121:699-705.
3. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., Daenen L.G., Man S., Xu P., Emmenegger U., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
4. Gingis-Velitski S., Loven D., Benayoun L., Munster M., Bril R., Voloshin T., Alishekevitz D., Bertolini F., Shaked Y. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011, 71:6986-6996.
5. Voloshin T., Voest E.E., Shaked Y. The host immunological response to cancer therapy: an emerging concept in tumor biology. Exp Cell Res 2013, 13:115-118.
6. Shaked Y., Kerbel R.S. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007, 67:7055-7058.
7. Shevchenko I., Karakhanova S., Soltek S., Link J., Bayry J., Werner J., Umansky V., Bazhin A.V. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013, 133:98-107.
8. Tran Cao H.S., Bouvet M., Kaushal S., Keleman A., Romney E., Kim G., Fruehauf J., Imagawa D.K., Hoffman R.M., Katz M.H. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 2010, 9:2068-2078.
9. Cham K.K., Baker J.H., Takhar K.S., Flexman J.A., Wong M.Q., Owen D.A., Yung A., Kozlowski P., Reinsberg S.A., Chu E.M., et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 2010, 103:52-60.
10. Kerbel R.S., Kamen B.A. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
11. Shaked Y., Emmengger U., Man S., Cervi D., Bertolini F., Ben-David Y., Kerbel R.S. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005, 106:3058-3061.
12. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003, 100:12917-12922.
13. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28:3617-3622.
14. Mace T.A., Ameen Z., Collins A., Wojcik S., Mair M., Young G.S., Fuchs J.R., Eubank T.D., Frankel W.L., Bekaii-Saab T., et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013, 73:3007-3018.
15. Shojaei F., Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008, 68:5501-5504.
16. Loven D., Hasnis E., Bertolini F., Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013, 18:193-201.
17. Shaked Y., Emmenegger U., Francia G., Chen L., Lee C.R., Man S., Paraghamian A., Ben David Y., Kerbel R.S., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005, 65:7045-7051.
18. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., Rawn K., Voskas D., Ben-David Y., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
19. Voloshin T., Gingis-Velitski S., Bril R., Benayoun L., Munster M., Milsom C., Man S., Kerbel R.S., Shaked Y. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 2011, 118:3426-3435.
20. Vives M., Ginesta M.M., Gracova K., Graupera M., Casanovas O., Capella G., Serrano T., Laquente B., Vinals F. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer 2013, 133:2464-2472.
21. Hackl C., Man S., Francia G., Milsom C., Xu P., Kerbel R.S. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2012, 62:259-271.
22. Fedele P., Marino A., Orlando L., Schiavone P., Nacci A., Sponziello F., Rizzo P., Calvani N., Mazzoni E., Cinefra M., et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 2012, 48:24-29.
23. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
24. Goedegebuure P., Mitchem J.B., Porembka M.R., Tan M.C., Belt B.A., Wang-Gillam A., Gillanders W.E., Hawkins W.G., Linehan D.C. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets 2011, 11:734-751.
25. Francia G., Shaked Y., Hashimoto K., Sun J., Yin M., Cesta C., Xu P., Man S., Hackl C., Stewart J., et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 2012, 11:680-689.
26. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008, 105:2640-2645.
27. + myeloid cells. Nat Biotechnol 2007, 25:911-920.
28. Zhao F., Obermann S., von Wasielewski R., Haile L., Manns M.P., Korangy F., Greten T.F. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009, 128:141-149.
29. Porembka M.R., Mitchem J.B., Belt B.A., Hsieh C.S., Lee H.M., Herndon J., Gillanders W.E., Linehan D.C., Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 2012, 61:1373-1385.
30. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005, 23:939-952.
31. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
32. Stromnes I.M., Brockenbrough J.S., Izeradjene K., Carlson M.A., Cuevas C., Simmons R.M., Greenberg P.D., Hingorani S.R. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014, (published online first Feb 2014 - in press).
33. Shaked Y., Voest E.E. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. Biochim Biophys Acta 2009, 1796:1-4.
34. Curtis V.F., Wang H., Yang P., McLendon R.E., Li X., Zhou Q.Y., Wang X.F. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS One 2013, 8:e54916.
35. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
36. Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012, 72:1103-1115.
37. Yang M., Li L., Jiang P., Moossa A.R., Penman S., Hoffman R.M. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc Natl Acad Sci U S A 2003, 100:14259-14262.
38. Katz M.H., Takimoto S., Spivack D., Moossa A.R., Hoffman R.M., Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003, 113:151-160.
39. Hoffman R.M., Yang M. Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc 2006, 1:928-935.
40. Sharma S.P. Avastin saga reveals debate over clinical trial endpoints. J Natl Cancer Inst 2012, 104:800-801.
41. Goozner M. Avastin hearing leads to more uncertainty over drug's future. J Natl Cancer Inst 2011, 103:1148-1150.